436 related articles for article (PubMed ID: 15510614)
1. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor rate, MIB-1 score and serum tumour markers CEA and CA 15-3 relationship in elderly women with pT1-2 breast cancer.
Lumachi F; Norberto L; Marino F; Basso SM; Marzano B; Chiara GB
Anticancer Res; 2010 Nov; 30(11):4701-4. PubMed ID: 21115927
[TBL] [Abstract][Full Text] [Related]
3. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer.
Lumachi F; Basso SM; Bonamini M; Marzano B; Milan E; Waclaw BU; Chiara GB
Anticancer Res; 2010 Jun; 30(6):2331-4. PubMed ID: 20651388
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.
Lumachi F; Brandes AA; Ermani M; Bruno G; Boccagni P
Anticancer Res; 2000; 20(6C):4751-5. PubMed ID: 11205212
[TBL] [Abstract][Full Text] [Related]
5. Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer.
Lumachi F; Ermani M; Marino F; Di Cristofaro L; Tombolan V; Brunello A; Roma A; Basso U
Anticancer Res; 2008; 28(1B):491-3. PubMed ID: 18383890
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
7. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
8. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment values of serum CA 15-3 antigen related to prognostic factors in breast cancer patients.
Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
Neoplasma; 1996; 43(4):225-9. PubMed ID: 8931745
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
11. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
12. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
17. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
20. [Level of CA 15-3 antigen--a prognostic factor in patients with breast cancer?].
Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
Przegl Lek; 1996; 53(11):788-92. PubMed ID: 9173440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
